Vera Therapeutics Stock Analysis

VERA Stock  USD 12.94  0.57  4.22%   
The main objective of Vera Therapeutics stock analysis is to determine its intrinsic value, which is an estimate of what Vera Therapeutics is worth, separate from its market price. There are two main types of Vera Therapeutics' stock analysis: fundamental analysis and technical analysis. Fundamental analysis focuses on the financial and economic factors that affect Vera Therapeutics' performance, such as revenue growth, earnings, and financial stability. Technical analysis, on the other hand, focuses on the price and volume data of Vera Therapeutics' stock to identify patterns and trends that may indicate its future price movements.
The Vera Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Vera Therapeutics is usually not traded on Memorial Day, Juneteenth Holiday, Independence Day, Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday. Vera Stock trading window is adjusted to America/New York timezone. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Vera Therapeutics' ongoing operational relationships across important fundamental and technical indicators.
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vera Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in producer price index.
For information on how to trade Vera Stock refer to our How to Trade Vera Stock guide.

Vera Stock Analysis Notes

About 97.0% of the company outstanding shares are owned by institutional investors. The book value of Vera Therapeutics was at this time reported as 2.78. The company recorded a loss per share of 2.86. Vera Therapeutics had not issued any dividends in recent years. Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California. Vera Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 29 people. For more information please call the company at 650 770 0077 or visit

Vera Therapeutics Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Vera Therapeutics' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Vera Therapeutics or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Vera Therapeutics generated a negative expected return over the last 90 days
Vera Therapeutics has high historical volatility and very poor performance
Net Loss for the year was (89.06 M) with profit before overhead, payroll, taxes, and interest of 0.
Vera Therapeutics currently holds about 131.93 M in cash with (67.6 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.86.
Vera Therapeutics has a frail financial position based on the latest SEC disclosures
Over 97.0% of the company outstanding shares are owned by institutional investors

Vera Therapeutics Upcoming and Recent Events

Earnings reports are used by Vera Therapeutics to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Vera Therapeutics previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
26th of March 2024
Upcoming Quarterly Report
9th of May 2024
Next Financial Report
31st of December 2023
Next Fiscal Quarter End
26th of March 2024
Next Fiscal Year End
30th of September 2023
Last Quarter Report
31st of December 2022
Last Financial Announcement

Vera Largest EPS Surprises

Earnings surprises can significantly impact Vera Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Fiscal Date
Estimated EPS
Reported EPS
View All Earnings Estimates

Vera Therapeutics SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Vera Therapeutics prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Vera Therapeutics investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Vera Therapeutics specific information freely available to individual and institutional investors to make a timely investment decision.
13th of November 2023
Unclassified Corporate Event
9th of November 2023
Financial Statements and Exhibits. Results of Operations and Financial Condition
10th of August 2023
Financial Statements and Exhibits. Results of Operations and Financial Condition
2nd of August 2023
Unclassified Corporate Event
5th of July 2023
Unclassified Corporate Event
20th of June 2023
Financial Statements and Exhibits. Other Events. Regulation FD Disclosure
16th of May 2023
Submission of Matters to a Vote of Security Holders
11th of May 2023
Financial Statements and Exhibits. Results of Operations and Financial Condition

Vera Therapeutics Thematic Classifications

In addition to having Vera Therapeutics stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
Pharmaceutical Products Idea
Pharmaceutical Products
USA Equities from Pharmaceutical Products industry as classified by Fama & French

Vera Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Vera Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Vera Therapeutics backward and forwards among themselves. Vera Therapeutics' institutional investor refers to the entity that pools money to purchase Vera Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Last TransactionTypeSharesValue
Commodore Capital Lp2023-09-30Common Shares5.5 M74.7 M
Fmr Llc2023-09-30Common Shares5.4 M74.7 M
Abingworth Llp2022-12-31Common SharesM57.3 M
Sofinnova Investments Inc2023-09-30Common Shares3.5 M47.5 M
Kynam Capital Management Lp2023-09-30Common SharesM40.5 M
Woodline Partners Lp2023-09-30Common Shares2.6 M35.1 M
Blackrock Inc2023-09-30Common Shares2.4 M32.3 M
State Street Corp2023-09-30Common Shares1.7 M23.7 M
Vanguard Group Inc2023-09-30Common Shares1.6 M21.6 M
Orbimed Advisors Llc2023-09-30Common Shares1.5 M20.8 M
Eversept Partners Lp2023-09-30Common Shares1.5 M20.3 M
Note, although Vera Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Vera Market Capitalization

The company currently falls under 'Small-Cap' category with a current market capitalization of 571.85 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Vera Therapeutics's market, we take the total number of its shares issued and multiply it by Vera Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.

Vera Profitablity

Vera Therapeutics' profitability indicators refer to fundamental financial ratios that showcase Vera Therapeutics' ability to generate income relative to its revenue or operating costs. If, let's say, Vera Therapeutics is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Vera Therapeutics' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Vera Therapeutics' profitability requires more research than a typical breakdown of Vera Therapeutics' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
Last ReportedProjected for 2023
Return on Average Assets(0.62)(0.67)
Return on Average Equity(0.81)(0.83)
Return on Invested Capital(1.07)(1.09)

Management Efficiency

Vera Therapeutics has return on total asset (ROA) of (0.4421) % which means that it has lost $0.4421 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.8959) %, meaning that it created substantial loss on money invested by shareholders. Vera Therapeutics' management efficiency ratios could be used to measure how well Vera Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of November 28, 2023, Return on Average Assets is expected to decline to -0.67. In addition to that, Return on Average Equity is expected to decline to -0.83. At present, Vera Therapeutics' Assets Non Current are projected to increase significantly based on the last few years of reporting. The current year's Tangible Assets Book Value per Share is expected to grow to 5.08, whereas Total Assets are forecasted to decline to about 109 M.
Last ReportedProjected for 2023
Book Value per Share 2.89  3.12 
Enterprise Value over EBIT(6.00)(6.47)
Enterprise Value over EBITDA(5.96)(6.43)
Price to Book Value 6.96  6.85 
Tangible Assets Book Value per Share 4.95  5.08 
Enterprise Value516.8 M561.3 M
Tangible Asset Value131.4 M109 M
The analysis of Vera Therapeutics' management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze Vera Therapeutics' future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of Vera Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.

Technical Drivers

As of the 28th of November, Vera Therapeutics has the Coefficient Of Variation of (1,446), variance of 20.06, and Risk Adjusted Performance of (0.045517). In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Vera Therapeutics, as well as the relationship between them. In other words, you can use this information to find out if the company will indeed mirror its model of past prices and volume data, or the prices will eventually revert. We were able to interpolate data for thirteen technical drivers for Vera Therapeutics, which can be compared to its competition. Please validate Vera Therapeutics market risk adjusted performance, variance, as well as the relationship between the Variance and value at risk to decide if Vera Therapeutics is priced more or less accurately, providing market reflects its prevalent price of 12.94 per share. Given that Vera Therapeutics has information ratio of (0.08), we advise you to double-check Vera Therapeutics's current market performance to make sure the company can sustain itself at a future point.

Vera Therapeutics Price Movement Analysis

Execute Study
The output start index for this execution was twenty-nine with a total number of output elements of thirty-two. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Vera Therapeutics middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Vera Therapeutics. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.

Vera Therapeutics Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Vera Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Vera Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Vera Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Vera Therapeutics Predictive Daily Indicators

Vera Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Vera Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Vera Therapeutics Forecast Models

Vera Therapeutics' time-series forecasting models are one of many Vera Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Vera Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Vera Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Vera Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Vera shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Vera Therapeutics. By using and applying Vera Stock analysis, traders can create a robust methodology for identifying Vera entry and exit points for their positions.
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California. Vera Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 29 people.

Current Vera Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Vera analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Vera analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
Vera Therapeutics current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Vera analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Vera stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Vera Therapeutics, talking to its executives and customers, or listening to Vera conference calls.
Vera Analyst Advice Details

Vera Stock Analysis Indicators

Vera Therapeutics stock analysis indicators help investors evaluate how Vera Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Vera Therapeutics shares will generate the highest return on investment. By understating and applying Vera Therapeutics stock analysis, traders can identify Vera Therapeutics position entry and exit signals to maximize returns.
Begin Period Cash Flow80 M
Long Term Debt24.8 M
Common Stock Shares Outstanding26.6 M
Total Stockholder Equity76.9 M
Total Cashflows From Investing Activities-70.6 M
Tax Provision1000.00
Property Plant And Equipment Net5.2 M
Cash And Short Term Investments114.7 M
Cash114.7 M
Accounts Payable12 M
Net Debt-83.4 M
50 Day M A12.393
Total Current Liabilities25.6 M
Other Operating Expenses90.9 M
Non Current Assets Total5.7 M
Common Stock Total Equity28 K
Non Currrent Assets Other506 K
Stock Based Compensation8.9 M
When determining whether Vera Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Vera Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Vera Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Vera Therapeutics Stock:
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vera Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in producer price index.
For information on how to trade Vera Stock refer to our How to Trade Vera Stock guide.
You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.

Complementary Tools for Vera Stock analysis

When running Vera Therapeutics' price analysis, check to measure Vera Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vera Therapeutics is operating at the current time. Most of Vera Therapeutics' value examination focuses on studying past and present price action to predict the probability of Vera Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vera Therapeutics' price. Additionally, you may evaluate how the addition of Vera Therapeutics to your portfolios can decrease your overall portfolio volatility.
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Share Portfolio
Track or share privately all of your investments from the convenience of any device
CEO Directory
Screen CEOs from public companies around the world
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Is Vera Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vera Therapeutics. If investors know Vera will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vera Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
Return On Assets
Return On Equity
The market value of Vera Therapeutics is measured differently than its book value, which is the value of Vera that is recorded on the company's balance sheet. Investors also form their own opinion of Vera Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Vera Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vera Therapeutics' market value can be influenced by many factors that don't directly affect Vera Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Vera Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Vera Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vera Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.